Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Biphenotypic, Acute 2Patient Preference 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2romidepsin 1decitabine and cedazuridine drug combination 1Vincristine 1Tomography, X-Ray Computed 1Prednisone 1Oxaliplatin 1Gemcitabine 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell, Peripheral × decitabine and cedazuridine drug combination × Clear all
NCT05403450 2026-02-23

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Taiho Oncology, Inc.

Phase 1 Active not recruiting
33 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡